The latest interim data from XPAND, AirXpanders Inc.’s U.S.-based, head-to-head pivotal study of its new, needle-free, patient-controlled tissue expansion system

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

New User Registration
 
 
 
 
 
 
*Required field